Home | Coriolis Pharma

Coriolis Pharma Formulating innovation

We enable innovative therapies by revolutionizing formulation development.

Formulation Development

“It is a medicine, not a molecule, that we are giving to the patient” Marc B. Brown, 2005.

Coriolis is the expert in developing liquid and lyophilized formulations for a large variety of different (bio)pharmaceutical molecules, including proteins, peptides, nucleic acids, ATMPs, GMOs, vaccines and virus(-like) particles.

Find out how we can support your drug development...

Analytical Services

A highly diverse analytical portfolio entirely performed in-house: This is Coriolis.

With the latest in technology and highly experienced scientists, we are a trendsetter in the field. We provide our analytical services for samples up to biosafety level S2 under R&D and cGMP conditions, including method development, qualification and validation.

Get to know our services...

About us

Independent, reliable and always on the cutting edge of science. Coriolis is a leading service provider for formulation research and development of (bio)pharmaceutical drugs and vaccines.

Get to know us...

2022/05/12

Protect the Virus!

Coriolis experts around Gideon Kersten publish opinion article about virus formulation in "The Medicine Maker"

2022/05/09

Coriolis participates at the AAPS National Biotechnology Conference

Meet our CSO Dr. Andrea Hawe and join her talk about "Surfactant Degradation: The Closer You Look The More You Learn"

2022/05/04

Coriolis Pharma Appoints Silvia Steyrer-Gruber as New Chief Executive Officer

The Appointment Marks a Next Step in the Organic Growth Journey of Coriolis Pharma

2022/04/20

Meet us at the PEGS Boston Conference

Meet our team at the Coriolis booth or visit us at the poster session

2022/04/14

Coriolis expert speaks at EIP Symposium in Portugal

Dr. Andrea Hawe will speak about the relevance of particle analysis for immunogenicity in biopharmaceuticals

2022/04/12

Journal of Pharmaceutical Science Publishes Special Issue in Memory of Wim Jiskoot

Coriolis contributed several publications to honor a great colleague and friend.

2022/04/06

Meet us at the PDA Visual Inspection Forum in Berlin

Our expert Dr. Jörg Müller is very looking forward to welcome you at the Coriolis booth!

2022/03/17

Coriolis Pharma and U-Medico Announce a Strategic Alliance

Coriolis Pharma (Martinsried, Germany) and U-Medico (Osaka, Japan) will join forces to provide science-driven and innovative formulation development services for clients worldwide.

2022/03/01

Prof. Dr. Paolo Arosio joins our Scientific Advisory Board

We welcome Prof. Dr. Paolo Arosio as a new Scientific Advisory Board Member and expert in protein aggregation and biophysical properties of biologics.

2022/02/01

Coriolis Pharma opens new ATMP formulation development facilities

Coriolis’ new ATMP facilities will meet the growing demand for formulation development and analytical characterization for ATMPs up to BSL2/S2 level and increase Coriolis’ capabilities significantly

View all

Latest publications

Assessing the Aggregation Propensity of Single-Domain Antibodies upon Heat-Denaturation Employing the ΔTm Shift

Patrick Kunz

Design of freeze-drying cycles: The determination of heat transfer coefficient by using heat flux sensor and MicroFD

Marco Carfagna, Monica Rosa, Andrea Hawe and Wolfgang Frieß

Systematic Studies on Stabilization of AAV Vector Formulations by Lyophilization

Ruth Riesera, Tim Menzen, Martin Biel, Stylianos Michalakis, Gerhard Winter

Assessing the Aggregation Propensity of Single-Domain Antibodies upon Heat-Denaturation Employing the ΔTm Shift

Patrick Kunz

Comparison of Submicron Particle Counting Methods with a Heat Stressed Monoclonal Antibody

Andreas Stelzl, Adam Grabarek, StefanSchneid, Wim Jiskoot †, Tim Menzen and Gerhard Winter

Particles in Biopharmaceutical Formulations, Part 2

Alexandra Roescha, Sarah Zölls, Daniela Stadler, Constanze Helbig, Klaus Wuchner, Gideon Kersten, Andrea Hawe, Wim Jiskoot and Tim Menzen

Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis?

Wim Jiskoot †, Andrea Hawe, Tim Menzen, David B. Volkin, Daan J.A. Crommelin

Development and Application of a Mechanistic Cooling and Freezing Model of the Spin Freezing Step within the Framework of Continuous Freeze-Drying

Gust Nuytten, Susan Ríos Revatta, Pieter-Jan Van Bockstal, Ashish Kumar, Joris Lammens, Laurens Leys, Brecht Vanbillemont, Jos Corver, Chris Vervaet and Thomas De Beer

An Interlaboratory Comparison on the Characterization of a Sub-micrometer Polydisperse Particle Dispersion

Kurt D Benkstein, Gurusamy Balakrishnan, Ashwinkumar Bhirde, Pascal Chalus, Tapan K Das, Ngoc Do, David L Duewer, Nazar Filonov, Fook Chiong Cheong, Patrick Garidel, Nicole S Gill, Adam D Grabarek, David G Grier, Judith Hadley, Andrew D Hollingsworth, Wesley W Howard, Maciej Jarzębski, Wim Jiskoot, Sambit R Kar, Vikram Kestens, Harshit Khasa, Yoen Joo Kim, Atanas Koulov, Anja Matter, Laura A Philips, Christine Probst, Yannic Ramaye, Theodore W Randolph, Dean C Ripple, Stefan Romeijn, Miguel Saggu, Franziska Schleinzer , Jared R Snell, Jan Kuba Tatarkiewicz, Heather Anne Wright, Dennis T Yang

Continuous milli-scale reaction calorimeter for direct scale-up of flow chemistry

Marlies Moser, Alain G. Georg, Finn L. Steinemann, David P. Rütti and Daniel M. Meier

View all

About us

Formulation Development

Analytical Services

About us

Latest news

Latest publications